US03589W1027

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025 22:55 ET  | Source: Annexon Biosciences BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”)…

3 weeks ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

August 07, 2025 16:30 ET  | Source: Annexon Biosciences New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions,…

4 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

June 18, 2025 16:05 ET  | Source: Annexon Biosciences Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and…

6 months ago